Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFZ533 add-on therapy in moderate to severe myasthenia gravis
2015-000097-35Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing CFZ533 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Mean change from baseline in Quantitative Myasthenia Gravis score at 24 weeks. Started Jun 2015; status: completed.
02
Drugs
iscalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2015-000097-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000097-35.